Aquestive Prepares for FDA Review of Anaphylm Resubmission
The company filed a resubmission of its NDA for Anaphylm, seeking to address FDA feedback, and updated investors on its AdrenaVerse pipeline during its corporate presentation.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed